Skin Permeation of Rosiglitazone from Transdermal Matrix Patches - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Skin Permeation of Rosiglitazone from Transdermal Matrix Patches
The authors demonstrate that sustained-release delivery can help avoid the risk of sudden higher-blood concentration of a drug to avoid toxicity.

Pharmaceutical Technology
Volume 34, Issue 5, pp. 56-72

Insulin resistance is a common feature characterizing the pathogenesis of Type 2 diabetes mellitus. Epidemiologic studies have found a strong association between insulin resistance and Type 2 diabetes (1). For example, more than 90% of African Americans, Hispanics, and nonhispanic whites with Type 2 diabetes in the United States were identified as insulin resistant (2). Rosiglitazone [()-5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione, (Z)-2-butenedioate (1:1)], a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control because it has a high affinity for peroxisome proliferators-activated receptor-gamma (PPARγ). Thus, it regulates the transcription of certain insulin-responsive genes and improves insulin sensitivity (3). It controls glucose production, transport, and utilization. Although recent studies claim that the drug could be a risk for cardiac patients, it is still a good option for improving insulin sensitivity (4–6).

Rosiglitazone is a weak base with a molecular weight of 357.44 Da. As a maleate salt, 2 to 8 mg of it is administered in tablet form twice daily, with or without a combination of metformin. However, rosiglitazone is metabolized extensively by n-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid in the liver (7, 8). Therefore, alternative routes such as transdermal delivery may be a good choice to deliver the drug directly into systemic circulation through intact skin by bypassing the hepatic first-pass effect to reduce dose frequency by maintaining a prolonged therapeutic blood level of rosiglitazone.

A transdermal patch is a medicated adhesive patch placed on the skin to deliver drugs into the bloodstream (9). The drug has a log P value of 2.1, which contributes to its lipid solubility and hydrophilicity. The oral absorption of rosiglitazone is 99%. Clearance of the drug, in terms of excretion in breast milk, is unknown; renal excretion of metabolized drug is 64%, and feces show the presence of about 23% of the parent compound. The elimination half-life of the drug is 3–4 h, and total protein binding is 99.8% to albumin. The drug has the volume of distribution of 17.6 L. These factors suggest that the drug is a suitable candidate for transdermal drug-delivery systems (TDDS). The authors evaluated the efficacy of the formulations in streptozotocin (STZ)-induced diabetic rats and examined the pharmacokinetic parameters of drug administered through TDDS in humans. This study describes how to develop a matrix–type transdermal patch containing rosiglitazone maleate using pressure-sensitive adhesives (Duro-Tak 387-2516 and Duro-Tak 87-2852). A blend of Duro-Tak polymers can achieve the desired consistency and tackiness for a TDDS, without any gelling agents. Duro-Tak polymers are acrylate-polymeric solutions containing acrylic acid, methyl acrylate, and 2-ethylhexyl acrylate at different ratios. In the present study, transdermal matrix patches containing rosiglitazone maleate using combinations of polymers Duro-Tak 387-2516 and Duro-Tak 87-2852 in ratios of 4:5 and 4:6 were developed and evaluated in vitro and in vivo.


Rosiglitazone maleate was obtained as a gift sample from Sun Pharma (Mumbai). Duro-Tak 387-2516 (a semisolid polymer with boiling point of 60 C, solid content of 41.5%, and viscosity of 4350 cp) and Duro-Tak 87-2852 (a semisolid polymer with a boiling point 65.5 C, solid content of 33.5%, and viscosity of 2550 cp) were gifts from the National Starch and Chemical Company (Bridgewater, NJ). Polyvinyl alcohol was purchased from S.D. Fine-Chem (Boisar, India). Streptozotocin (STZ) was purchased from Sigma-Aldrich (Bangalore, India). All other chemicals used were of analytical reagent grade.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here